These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26073580)

  • 1. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
    Calcagno A; D'Avolio A; Bonora S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir as antiretroviral therapy in HIV/AIDS.
    Sharma M; Walmsley SL
    Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors.
    Psichogiou M; Poulakou G; Basoulis D; Paraskevis D; Markogiannakis A; Daikos GL
    Curr Pharm Des; 2017; 23(18):2552-2567. PubMed ID: 28356041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of HIV infection with raltegravir.
    Chirch LM; Morrison S; Steigbigel RT
    Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S
    Curr HIV Res; 2016; 14(1):54-60. PubMed ID: 26415700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH; Markowitz M
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
    Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
    Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of dolutegravir safety for the treatment of HIV-1.
    Keeshin SW; Feinberg J
    Expert Opin Drug Saf; 2015 Jan; 14(1):141-7. PubMed ID: 25347230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
    Pendri A; Meanwell NA; Peese KM; Walker MA
    Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years' real-life experience with raltegravir in a large HIV centre.
    van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
    Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrase Resistance-Associated Mutations on Raltegravir Failure in Western India: A Preliminary Analysis.
    Pujari SN; Gaikwad S; Joshi K; Dabhade D; Sane S; Rao NP; Bele V
    J Acquir Immune Defic Syndr; 2018 Apr; 77(5):e42-e45. PubMed ID: 29315113
    [No Abstract]   [Full Text] [Related]  

  • 15. Raltegravir: an integrase inhibitor for HIV-1.
    Evering TH; Markowitz M
    Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 17. Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.
    Maliakkal A; Walmsley S; Tseng A
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):153-61. PubMed ID: 27183177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.
    Brown AN; Adams JR; Baluya DL; Drusano GL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3771-7. PubMed ID: 25870053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
    Podany AT; Scarsi KK; Pham MM; Fletcher CV
    Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.